US Patent Issued to The Board of Regents of the University of Oklahoma on Sept. 16 for "Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof" (Oklahoma Inventor)

ALEXANDRIA, Va., Sept. 17 -- United States Patent no. 12,415,867, issued on Sept. 16, was assigned to The Board of Regents of the University of Oklahoma (Norman, Okla.).

"Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof" was invented by Courtney W. Houchen (Edmond, Okla.).

According to the abstract* released by the U.S. Patent & Trademark Office: "CAR cells and humanized antibodies targeting DCLK1 expressed on/in tumor cells or circulating cancer cells are described as a new method of cancer treatment. The antibodies and cells are safe and effective in patients and can be used to treat cancer expressing the DCLK1 proteins."

The patent was filed on Jan. 30, 2024, under Application No. 18/42...